Highlights
- EPS (TTM)
- -$2.09
- Total Revenue (TTM)
- $6.00K
- Gross Profit (TTM)
- -$179.00K
- EBITDA (TTM)
- -$4.01M
- Year Range
- $1.67 - $6.20
- ROA (TTM)
- -135.70%
- ROE (TTM)
- -186.95%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Alaunos Therapeutics Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Alaunos Therapeutics Inc (TCRT) has returned -11.46% so far this year and 94.56% over the past 12 months. Over the last ten years, TCRT has returned -45.07% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.
Alaunos Therapeutics Inc
- 1D
- 1.42%
- 1M
- -10.34%
- YTD
- -11.46%
- 6M
- 18.67%
- 1Y
- 94.56%
- 3Y*
- -68.84%
- 5Y*
- -65.00%
- 10Y*
- -45.07%
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Aug 24, 2005, TCRT's average daily return is +0.04%, while the average monthly return is +0.50%. At this rate, your investment would double in approximately 11.6 years.
Historically, 46% of months were positive and 54% were negative. The best month was May 2009 with a return of +145.4%, while the worst month was Aug 2005 at -97.5%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 8 months.
On a daily basis, TCRT closed higher 44% of trading days. The best single day was Oct 10, 2008 with a return of +63.3%, while the worst single day was Aug 25, 2005 at -97.5%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -18.58% | 21.29% | -10.34% | -11.46% | |||||||||
| 2025 | -10.76% | -8.82% | -5.16% | 66.67% | 0.41% | 97.15% | -41.24% | -25.26% | 13.15% | 12.86% | 22.79% | -3.29% | 69.55% |
| 2024 | 138.47% | -17.36% | -13.40% | -30.39% | -13.49% | -35.87% | -47.35% | -29.62% | 24.32% | -36.34% | 25.85% | -26.16% | -82.04% |
| 2023 | 13.79% | -24.86% | 13.51% | -9.52% | -12.47% | 2.22% | -15.25% | -67.38% | -6.52% | -39.30% | -17.25% | 6.80% | -89.11% |
| 2022 | -0.92% | -8.71% | -33.83% | -18.55% | -2.56% | 139.47% | -5.65% | 110.26% | -30.08% | -33.14% | -44.52% | 1.74% | -40.45% |
| 2021 | 47.22% | 43.67% | -32.46% | -3.89% | -12.14% | -13.16% | -14.02% | -28.19% | 11.66% | -17.58% | -7.33% | -21.58% | -56.75% |
Benchmark Metrics
Alaunos Therapeutics Inc has an annualized alpha of 0.17%, beta of 0.94, and R² of 0.03 versus S&P 500 Index. Calculated based on daily prices since August 25, 2005.
- This stock participated in 157.90% of S&P 500 Index downside but only -57.53% of its upside — more exposed to losses than it benefited from rallies.
- R² of 0.03 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 0.17%
- Beta
- 0.94
- R²
- 0.03
- Upside Capture
- -57.53%
- Downside Capture
- 157.90%
Return for Risk
Risk / Return Rank
TCRT ranks 70 for risk / return — better than 70% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Alaunos Therapeutics Inc (TCRT) and compare them to a chosen benchmark (S&P 500 Index).
| TCRT | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.75 | 0.90 | -0.14 |
Sortino ratioReturn per unit of downside risk | 1.97 | 1.39 | +0.59 |
Omega ratioGain probability vs. loss probability | 1.24 | 1.21 | +0.03 |
Calmar ratioReturn relative to maximum drawdown | 1.46 | 1.40 | +0.06 |
Martin ratioReturn relative to average drawdown | 2.37 | 6.61 | -4.24 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore TCRT risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Alaunos Therapeutics Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Alaunos Therapeutics Inc was 100.00%, occurring on Mar 14, 2025. The portfolio has not yet recovered.
The current Alaunos Therapeutics Inc drawdown is 100.00%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -100% | Aug 25, 2005 | 4919 | Mar 14, 2025 | — | — | — |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Alaunos Therapeutics Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Alaunos Therapeutics Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for TCRT relative to other companies in the Biotechnology industry. Currently, TCRT has a P/S ratio of 919.8. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |